Two Views of Sans Rosa - G. Nase

SansRosa is a full go. Pharmaceutical companies don't usually talk to anyone at these stages and if so, dont want to give anything out at all except to scientists or physicians, otherwise they find other companies right on their heals filing for a new drug application even though SansRosa did all the work. This is so commonplace. My discussions have been completely the opposite and I have first hand reports from actual testers (4 testers who are on this group that have contacted me). 3 of them literally said this was a life changing topical for them with regards to permanent redness, telangiectasia, and flushing was greatly reduced. The fouth one had mixed results -- some positive and some that may indicated he experienced a little bit of rebound effect. But the first pre-clinical studies were so impressive that Mayo has taken the reigns from now on -- that means a heck of a lot in itself. The first series of larger clinical studies were a complete success with all expectations being met. As any company they wilil keep on tweaking the drug throught the first II phases. Notice, it you hit the Internet, there is almost zilch on this product -- that is the way they want it because until they file a New Drug Application or Trademark down the road, it is literally free game. Plus if David was speaking to Jim Fey, I believe he has never been so overwhelmed with phone calls and is now taking a general conservative policy regarding statements -- which is actually the proper way to go for right now until they have a hold of the drug themselves. Companies swipe drugs right from underneath smaller ones too many times. As for timing, if each trial is as successful as the first two this will go very fast becase it has already been approved for human use (huge plus) and been approved for one of the hardest organs to get approved, the eyes (huge plus showing its safety), plus with superfiicial vessels in the eye there was no rebound dilation. I also have first hand experience with this substance, as does Dr. Hein, and it makes perfect sense why and how this would work. This product will not take three to four years as David speculated himself -- cut that in half. They are already recruiting for larger multicenter studies which pushed them right up on the original time frame. Its all good!
Geoffrey ----------------------
-------------------------- Dr. Geoffrey Nase